ABSTRACT
At present,splenectomy and extensive esophagogastric devascularization is one of the effective treatments for relieving hypersplenism in patients with cirrhosis,relieving portal hypertension,and reducing upper gastrointestinal bleeding caused by rupture of esophagogastric varices.However,portal vein thrombosis is one of the most common serious complications of splenectomy and devascularization in patients with cirrhosis.Because of its high incidence and mortality of PVT,it has become the focus of disputes in the surgical field.In recent years,with the improvement of medical technology,many domestic and foreign scholars have conducted high-quality researches on the prevention of PVT in the perioperative period of splenectomy and devascularization.This paper summarized the research progress during recent years in combination with relevant literature.
ABSTRACT
Objective To investigate the safety and efficacy of hepatitis B surface antigen (HBsAg) positivity of the donors on graft survival and liver complications in HBsAg (+) renal transplant recipients.Methods We retrospectively evaluated 96 HBsAg (+) patients who received HBsAg(+) donor kidney transplant fellow-up during 20～ 139 months,in order to observe the renal allograft dysfunction,liver dysfunction and others complications.Results All 96 patients underwent renal transplantation successfully in our hospital.during the follow-up period,18 cases accepted entecavir-treated,one case lost graft function,two cases died,one of them developed drug resistance and liver function failure,the other because of cancer of the liver.Twenty-three of the 78 lamivudinetreated patients (29.5％) developed drug resistance in 7～96 months,and 3 cases developed liver function failure,2 cases died and one cured,15 of the 19 cases who been salvage treated with entecavir was successful and well tolerated after 1 year,2 cases who been salvage treated with adefovir and lamivudine with HBV DNA-negative after 12 months and 23 months.The 5-year patient/graft rates of patients who been treated with lamivudine and entecavir were 88.5％/84.6％ and 88.9％/83.3％ respectively.Conclusion It is safe and feasible for renal transplantation from HBsAg(+) donors to HBsAg(+) recipients with antiviral treatment,patients would require lifelong anti-viral suppression and strictly follow-up,which is important for patient and graft survival,anti-viral drugs resistance and the liver complications should be closely monitored and treated.
ABSTRACT
Objective To investigate the effect of ursodesoxycholic acid (UDCA) on JAK/STAT3/ COX-2 signal pathway in human hepatocellular carcinoma cells and the underlying mechanism of its antitumor effect.Methods In order to obtain the optimal concentration and time of UDCA,MTT assay was used to detect anti-proliferative activities of UDCA on SMMC-7721 cells induced by IL-6 in vitro.Cells were divided into control group,IL-6 group,AG490 (JAK2 inhibitor) group and UDCA group.The protein expressions of STAT3,p-STAT3 and COX-2 were measured by Western blot.Results MTT assay showed UDCA had obvious anti-proliferative activities on SMMC-7721 cells.The optimized concentrations were 50,100,200 μg/ml,the optimized culture time was 48 h.Western blot results showed that the expression of p-STAT3 and COX-2 were remarkably increased in IL-6 group than that in control group.There was no difference of STAT3 expression between the two groups.Compared with IL-6 group,the protein level of COX-2 was decreased in AG490 and UDCA groups,so was the expression of p-STAT3.But there was no change on STAT3 expression in AG490 and UDCA groups.Conclusion UDCA may decrease the proliferation of SMMC-7721 cells via inhibiting phosphorylation of STAT3 and down-regulating COX-2 exprcssion.